Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- Nine important updates in colorectal canceron March 28, 2020 at 4:49 am
Colorectal Cancer Awareness Month is observed in March. The observance is intended to increase awareness about the prevalence of the disease, its symptoms, and the key role screening plays in ...
- Mrs. Arizona 2020 changes stigma of colon cancer after being diagnosedon March 27, 2020 at 9:12 pm
Her name is Jennifer Ruddle. She reigns as the United States of America's Mrs. Arizona 2020. And sitting on top of a mountain with sweeping views ...
- Rectal Cancer - Global Pipeline Review, H1 2020 - ResearchAndMarkets.comon March 27, 2020 at 4:15 am
Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This pipeline guide, Rectal Cancer - Pipeline Review, H1 2020 provides comprehensive information on the ...
- Guidelines on Delaying Cancer Surgeryon March 26, 2020 at 9:48 am
These cases include patients with a nearly obstructing colon cancer where stenting is not an option; those with nearly obstructing rectal cancer (should be diverted); cancers with high (inpatient) ...
- Regulation of the small GTPase Ran by miR-802 modulates proliferation and metastasis in colorectal cancer cellson March 24, 2020 at 4:10 pm
The small GTPase Ran is upregulated in multiple cancers and fundamental for cancer cell survival and progression, but its significance and molecular mechanisms in colorectal cancer (CRC) remain ...
- Indiana lowers minimum colorectal cancer screening ageon March 24, 2020 at 3:30 pm
A new Indiana law requires health insurance companies, in most circumstances, to cover colorectal cancer screening beginning at age 45, instead of 50.
- Sisters Share Colon Cancer Screening Message for Younger Adultson March 24, 2020 at 11:29 am
One of your neighbors posted in Health & Fitness. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal canceron March 24, 2020 at 3:16 am
Body fatness increases the risk of colorectal cancer (CRC) 1,2. Mendelian randomization studies have consistently inferred the association as causal 3,4, but the underlying biology is not fully ...
- Study: Any Polyps Raise Risk of Colorectal Canceron March 23, 2020 at 10:35 am
Patients with any polyp subtype had a higher risk than the general population of developing colorectal cancer (CRC) in a Swedish cohort that had generally not been previously screened, a large ...
- As colon cancer rises among the young, South Loop man’s doctors try an old tool in a new wayon March 19, 2020 at 10:00 pm
Sean O’Reilly faces a tough fight but says: ‘Negativity leads nowhere. . . . I don’t view this as a death sentence anymore, I view it as: I’m going to beat it, or I’m going to live with it.’ Sometimes ...
via Google News and Bing News